How to define valvular atrial fibrillation?

Arch Cardiovasc Dis. 2015 Oct;108(10):530-9. doi: 10.1016/j.acvd.2015.06.002. Epub 2015 Jul 14.

Abstract

Atrial fibrillation (AF) confers a substantial risk of stroke. Recent trials comparing vitamin K antagonists (VKAs) with non-vitamin K antagonist oral anticoagulants (NOACs) in AF were performed among patients with so-called "non-valvular" AF. The distinction between "valvular" and "non-valvular" AF remains a matter of debate. Currently, "valvular AF" refers to patients with mitral stenosis or artificial heart valves (and valve repair in North American guidelines only), and should be treated with VKAs. Valvular heart diseases, such as mitral regurgitation, aortic stenosis (AS) and aortic insufficiency, do not result in conditions of low flow in the left atrium, and do not apparently increase the risk of thromboembolism brought by AF. Post-hoc analyses suggest that these conditions probably do not make the thromboembolic risk less responsive to NOACs compared with most forms of "non-valvular" AF. The pathogenesis of thrombosis is probably different for blood coming into contact with a mechanical prosthetic valve compared with what occurs in most other forms of AF. This may explain the results of the only trial performed with a NOAC in patients with a mechanical prosthetic valve (only a few of whom had AF), where warfarin was more effective and safer than dabigatran. By contrast, AF in the presence of a bioprosthetic heart valve or after valve repair appears to have a risk of thromboembolism that is not markedly different from other forms of "non-valvular" AF. Obviously, we should no longer consider the classification of AF as "valvular" (or not) for the purpose of defining the aetiology of the arrhythmia, but for the determination of a different risk of thromboembolic events and the need for a specific antithrombotic strategy. As long as there is no better new term or widely accepted definition, "valvular AF" refers to patients with mitral stenosis or artificial heart valves. Patients with "non-valvular AF" may have other types of valvular heart disease. One should emphasize that "non-valvular AF" does not exclude patients with some types of valvular heart disease from therapy with NOACs.

Keywords: Accident vasculaire cérébral; Atrial fibrillation; Fibrillation atriale; Stroke; Valve disease; Valvulopathie.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / classification*
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / etiology*
  • Bioprosthesis
  • Fibrinolytic Agents / therapeutic use
  • Heart Valve Diseases / complications*
  • Heart Valve Diseases / diagnosis
  • Heart Valve Diseases / surgery
  • Heart Valve Prosthesis
  • Heart Valve Prosthesis Implantation / adverse effects*
  • Heart Valve Prosthesis Implantation / instrumentation
  • Humans
  • Practice Guidelines as Topic
  • Prosthesis Design
  • Risk Assessment
  • Risk Factors
  • Stroke / diagnosis
  • Stroke / etiology*
  • Stroke / prevention & control
  • Terminology as Topic*
  • Thromboembolism / diagnosis
  • Thromboembolism / etiology*
  • Thromboembolism / prevention & control
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents